Can prognosis be altered by treating LV dysfunction?
A major scientific effort taking place in the last decade has resulted in better understanding of the pathophysiology of myocardial dysfunction and in the development of new therapeutic modalities for this condition. The purpose of this article is to review available information related to the effect of available therapeutic modalities on mortality rate in patients with left ventricular (LV) systolic dysfunction.
Elkayam
U
U
Department of Medicine, LAC-USC Medical Center, University of Southern California School of Medicine 90033.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D011379:Prognosis; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D004232:Diuretics; D014665:Vasodilator Agents